Laboratorios Rubió Increases Sales by 40% in 2022 and Exceeds €100 million

Laboratorios Rubió skyrockets its sales. The Catalan pharmaceutical company closed the 2022 financial year with a turnover of €108.1 million, which translates into an increase of 40%. 70% of the income comes from the sale of its products in pharmacies; 12% are hospital products, while about 18% correspond to other sales channels. The forecast for this year is to grow 6.5%, according to Expansión.

The Catalan company closed 2022 with a profit of €5 million, which translates into an increase of 31.6%. Likewise, during the last fiscal year, the pharmaceutical company opened subsidiaries in the United States and Italy. The gross operating result (EBITDA) was €7.1 million, compared to €5.5 million in 2021.

Rubió’s own funds stood at €17.7 million, 35% more. Long-term debts with credit institutions increased to €27 million, 22% more, while short-term debts reached €5.7 million, equivalent to an increase of 42%.

The laboratory specializes in prescription products in different areas such as the digestive system, the central nervous system, nephrology, and cardiovascular. It also has diagnostic products and has recently entered the food supplements market.

If you want to read more about Laboratorios Rubió and to find the most important financial news of the day, download for free our companion app Born2Invest.

Laboratorios Rubió has 82% of its business in Spain

The pharmaceutical company entered the nutritional supplements market in 2021 when it acquired the Spanish Fisiopharma from its founders for an approximate price of €15 million.

Through Fisipharma, Rubió bought a business of this type of product from the Italian Seikou Strategics last year for €350,000. On the other hand, the laboratory also strengthened its diagnostic division last year with the purchase of Frentix Invest

Laboratorios Rubió has 82% of the business in Spain and the rest abroad, with commercial agreements in sixty countries. In this sense, it has accelerated international growth this year with the opening of a subsidiary in the United States with the company ACS-OWL to market the OWLiver diagnostic product. It also created the Rubió Nutraceuticals subsidiary in Italy to market probiotics.

Laboratorios Rubió, founded in 1968 by the brothers Salvador and Pelayo Rubió, has its headquarters in Castellbisbal (Barcelona). The company has a staff of 200 workers. Last year it invested €4.8 million in research and development (R&D), which represents 4.44% of turnover. 

__

(Featured image by PublicDomainPictures via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.